“달서오피👼 〔OPDAL050.컴〕오피달리기 😋달서안마🌽달서풀싸롱🎟달서아로마🌨달서립카페👙달서마사지😼달서키스방🐝”的搜索结果，显示 371-380 项，共有 15646 项

1. 过敏科- 临床试验- 妙佑医疗国际

   Allergic and immunologic disorders are very common but some are very poorly understood. Numerous studies of the epidemiology, characteristics, diagnosis and ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. The purpose of this study is to find out more about certain markers of immune suppression in people with kidney tumors (whether the tumors are ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. The purpose of this study is to find out more about the side effects of the CAR-T therapy called IC19/1563 and what dose of IC19/1563 is safe ...

7. 乳腺癌- 医生与科室- 妙佑医疗国际

   这部分内容没有英语版本。 这部分内容没有阿拉伯语版本。

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...